Cardiology Research and Practice

Review Article

Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis

Table 1

Randomized controlled trial studies included in the systematic review and meta-analysis.
AuthorYearCountryDesign patientsInclusionDurationExperimentalControlOutcomes
InterventionNAgeInterventionNAge
Chen et al. [13]2020ChinaRCTHFrEF + T2DM24 wDAPA 10 mg/d + RT9665.14 ± 9.24Placebo + RT9466.37 ± 10.04①②③⑦⑧
Chen et al. [14]2020ChinaRCTHFmrEF + T2DM12 wDAPA 10 mg/d + RT4664.1 ± 6.3Placebo + RT4163.7 ± 6.7⑦
Dai et al. [15]2020ChinaRCTHFmrEF + T2DM24 WDAPA 5 mg/d + RT2467 ± 6.8Placebo + RT2666 ± 7.1⑦⑧
Kato et al. [12]2019AmericaRCTHFrEF + T2DM219 wDAPA 10 mg/d + RT31863Placebo + RT35163①②③④⑤⑥
Li [16]2020ChinaRCTHFmrEF + T2DM12 wDAPA 5 mg/d + RT2558.37 ± 5.39Placebo + RT2558.46 ± 5.41⑦⑧
McMurray et al. [10]2019EnglandRCTHFrEF78 wDAPA 10 mg/d + RT237366.2 ± 11.0Placebo + RT237166.5 ± 10.8①②③④⑤⑥
Nassif et al. [11]2019AmericaRCTHFrEF12 wDAPA 10 mg/d + RT13162.2 ± 11.1Placebo + RT13260.4 ± 12.0①②③④⑤
Tong et al. [17]2020ChinaRCTHFmrEF + T2DM24 wDAPA 10 mg/d + RT6070.2 ± 9.6Placebo + RT6068.5 ± 5.8⑦⑧
Yang et al. [18]2019ChinaRCTHFrEF + T2DM24 wDAPA 5 mg/d + RT5266.31 ± 8.53Placebo + RT5365.18 ± 8.37①②③④⑤⑥⑦
① Cardiovascular death/hospitalization for heart failure (CV death/HHF), ② cardiovascular death, ③ hospitalization for heart failure, ④ hypoglycemia, ⑤ volume depletion, ⑥ urinary tract infection, ⑦ left ventricular ejection fraction (LVEF), and ⑧ NT-proBNP. RCT: randomized controlled trial; T2DM: type 2 diabetes; HFrEF: heart failure with reduced ejection fraction; HFmrEF: midrange ejection fraction heart failure; DAPA: dapagliflozin; RT: basic recommended therapy.